Analgesic efficacy of valdecoxib for acute postoperative pain after bunionectomy

Journal of the American Podiatric Medical Association

Volumn 96, Issue 5, 2006, Pages 393-407

  Pollak, Richard ^a   Raymond, Gary A ^b   Jay, Richard M ^c   Hillstrom, Howard J ^c,d   Mahan, Kieran T ^c   Riff, Dennis ^e   Jacobs, Ellis L ^f   Brown, Mark T ^g   Verburg, Kenneth M ^g  

^a San Antonio Podiatry Associates   (United States)

^b Advanced Regional Center for Clinical Research   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

^e AGMG Clinical Research   (United States)

^f Horizon Institute for Clinical Research   (United States)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33749337611     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/0960393     Document Type: Article

References (28)

1. KEHLET H, DAHL JB: The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. Anesth Analg 77: 1048, 1993.
2. BANNWARTH B: Risk-benefit assessment of opioids in chronic noncancer pain. Drug Saf 21: 283, 1999.
3. GABRIEL SE, JAAKKIMAINEN L, BOMBARDIER C: Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 115: 787, 1991.
4. GAJRAJ NM: Cyclooxygenase-2 inhibitors. Anesth Analg 96: 1720, 2003.
5. GARCIA RODRIGUEZ LA, JICK H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343: 769, 1994.
6. GOLDSTEIN JL, SILVERSTEIN FE, AGRAWAL NM, ET AL: Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 95: 1681, 2000.
7. HARRIS SI, KUSS M, HUBBARD RC, ET AL: Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 23: 1422, 2001.
8. KIVITZ A, EISEN G, ZHAO WW, ET AL: Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 51: 530, 2002.
9. SIKES DH, AGRAWAL NM, ZHAO WW, ET AL: Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 14: 1101, 2002.
10. NOVECK RJ, LAURENT A, KUSS M, ET AL: Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals: two randomised, controlled trials. Clin Drug Invest 21: 465, 2001.
11. LEESE PT, TALWALKER S, KENT JD, ET AL: Valdecoxib does not impair platelet function. Am J Emerg Med 20: 275, 2002.
12. LEESE PT, RECKER DP, KENT JD: The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol 43: 504, 2003.
13. BROOM DC, SAMAD TA, KOHNO T, ET AL: Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain. Neuroscience 124: 891, 2004.
14. SAMAD TA, MOORE KA, SAPIRSTEIN A, ET AL: Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity [letter]. Nature 410: 471, 2001.
15. WOOLF CJ, COSTIGAN M: Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci U S A 96: 7723, 1999.
16. WOOLF CJ, SALTER MW: Neuronal plasticity: increasing the gain in pain. Science 288: 1765, 2000.
17. WOOLF CJ, MANNION RJ: Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353: 1959, 1999.
18. NEUMANN S, DOUBELL TP, LESLIE T, ET AL: Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature 384: 360, 1996.
19. SEIBERT K, ZHANG Y, LEAHY K, ET AL: Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91: 12013, 1994.
20. HAY C, DE BELLEROCHE J: Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord. Neuroreport 8: 1249, 1997.
21. DESJARDINS PJ, SHU VS, RECKER DP, ET AL: A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology 97: 565, 2002.
22. CAMU F, BEECHER T, RECKER DP, ET AL: Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 9: 43, 2002.
23. REYNOLDS LW, HOO RK, BRILL RJ, ET AL: The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. J Pain Symptom Manage 25: 133, 2003.
24. JOSHI GP, VISCUSI ER, GAN TJ, ET AL: Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Anesth Analg 98: 336, 2004.
25. GAN TJ, JOSHI GP, ZHAO SZ, ET AL: Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects. Acta Anaesthesiol Scand 48: 1194, 2004.
26. ZHAO SZ, CHUNG F, HANNA DB, ET AL: Dose-response relationship between opioid use and adverse effects after ambulatory surgery. J Pain Symptom Manage 28: 35, 2004.
27. GAN TJ, JOSHI GP, VISCUSI E, ET AL: Preoperative parenteral parecoxib and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery. Anesth Analg 98: 1665, 2004.
28. JENKINS JK, SELIGMAN PJ: Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk [memorandum]. Available at: http://www.fda.gov/cder/drug/infopage/COX2/ NSAIDdecisionMemo.pdf. Accessed June 20, 2005.